Earlier this week the Faculty of Pain Medicine at the Australian and New Zealand College of Anaesthetists (ANZCA) published guidance for health practitioners recommending against the prescription of medicinal cannabis for the treatment of chronic non-cancer pain (CNCP).

The recommendation is based on the current lack of high-quality evidence demonstrating medicinal cannabis products are effective for treating CNCP conditions.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

The fact that much more research needs to be conducted is indisputable. As is the fact that the current evidence – though promising – is still a far cry from the conventional data physicians are used to relying on.

Cannabiz editor-at-large Rhys Cohen

Unfortunately, Dr Michael Vagg (Dean of the Faculty of Pain Medicine) in an article in The Conversation, went much further than this. And in doing so he made some arguments that do not stand up to logical scrutiny.

Dr Vagg’s article is structured around busting three “myths” about medicinal cannabis. These are:

  1. Evidence shows cannabis products are effective for chronic pain
  2. Cannabis products should be provided as a ‘last resort’
  3. Medicinal cannabis may help with the opioid crisis

Let’s interrogate some of the claims he makes in each of those sections.

1) Evidence shows cannabis products are effective for chronic pain

Several placebo-controlled randomised controlled trials (RCTs) have investigated the potential of THC-containing cannabis medicines to treat chronic pain and found that medicinal cannabis can, in some cases, be effective. Based on the clinical research we have so far, the Therapeutic Goods Administration (TGA) argues that:

“We can be moderately confident that CNCP patients receiving medicinal cannabis are more likely to achieve 30% and 50% reductions in pain and to report a reduction in pain ratings than patients given a placebo.”

Rhys Cohen

As well as being editor-at-large at Cannabiz, Rhys is the director of Cannabis Consulting Australia, which provides commercial consulting services to various domestic and international cannabis companies....